[Fig 5a](#pone.0192059.g001){ref-type="fig"} is incorrect. The authors have provided a corrected version here.

![Combination of MEK and ERK inhibitors results in stronger suppression of KRAS mutant tumor growth due to improved suppression of MAPK output.\
**(a)** Combination of cobimetinib and GDC-0994 demonstrates significantly greater anti-tumor activity in multiple KRAS mutant tumor models A549 and NCI-H2122 (cobimetinib at 5 mg/kg, PO, QD + GDC-0994 at 60 mg/kg, PO, QD) compared to single agent (upper panels). Mean tumor volume is plotted ± SEM (n = 10 mice per group). Study was terminated on day 20. All treatments were tolerated with minimal body weight loss (lower panels), One way ANOVA, \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.005, \*\*\*\*p\<0.001. **(b)** A549 (NSCLC, KRAS^G12S^) tumor-bearing mice (n = 3 per time point) were treated with GDC-0994 (60 mg/kg, PO, QDx4), cobimetinib (GDC-0994; 5 mg/kg, PO, QDx4) or the combination and then MAPK target genes expression was assessed in tumor samples (Nanostring^®^) and the quantified results are plotted for each individual gene over time. The combination results in deeper, more prolonged suppression of multiple MAPK target genes, including *DUSP4*, *DUSP6*, *SPRY2*, *SPRY4*, *ETV4*, and *ETV5*. Student's t test at the 24 hr time point, \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.005, \*\*\*\*p\<0.001. **(c)** The combination of cobimetinib and GDC-0994 results in stronger and more prolonged suppression of p-p90RSK/total p90RSK phosphorylation (as determined by quantitative western blot), cyclin D1 and Ki-67, as well as increased induction of cleaved caspase 3 (CC3) (as determined by IHC) in A549 xenograft tumors treated for 4 days (values were quantified from n = 4 mice/time point). Student's t test at the 24 hr time point, \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.005.](pone.0192059.g001){#pone.0192059.g001}
